Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Offers $925M in Senior Notes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America said after the close of the market Tuesday that it is offering $925 million in senior notes.

It intends to use the proceeds to fund part of its purchase of Genzyme Genetics. The $925 million all cash deal was announced in September.

Funds from the offering will also go toward general corporate use, the company said.

The offering consists of two tranches: $325 million of 3.125 percent notes due 2016, and $600 million of 4.625 percent notes due 2020. The notes will bear interest from Nov. 19, 2010, payable semi-annually on May 15 and Nov. 15, beginning May 15, 2011.

The notes will be unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt, the company said.

The active joint book-running manager for the offering is Citigroup Global Markets. Barclays Capital and Merrill Lynch, Pierce, Fenner & Smith are passive joint book-running managers. The offer is subject to market and other conditions.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.